![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Introduction: Understanding of the underlying mechanisms of renal cell carcinoma (RCC) has increased dramatically over the past few years, leading to the development of several targeted biological therapies. Pazopanib is an orally available multi-tyrosine kinase inhibitor that inhibits VEGF receptors 1, 2 and 3, platelet-derived growth factor receptors α and β and the cytokine receptor, KIT. Pazopanib was first approved in the US for the treatment of advanced RCC in 2009.
Areas covered: This review discusses the scientific rationale for the use of pazopanib in advanced RCC, summarising pre-clinical and clinical study data, including results from the most recent Phase III clinical studies. The design of future clinical studies for pazopanib is also discussed.
Expert opinion: The efficacy and safety of pazopanib have been demonstrated in several clinical trials, as well as non-inferiority to sunitinib for progression-free survival. Pazopanib could become the most commonly used drug for first-line therapy of advanced RCC.
Acknowledgements
Editorial support was provided by Joanne Parker of Fishawack Indicia Ltd, funded by GlaxoSmithKline. GlaxoSmithKline had no involvement in the writing or review of this manuscript.
Declaration of interest
Professor B Escudier has served as a consultant for GlaxoSmithKline, Pfizer, Novartis and Bayer. Dr L Albiges has received research funding from Pfizer and Novartis and has taken part in advisory boards for Pfizer, Novartis, Amgen and Sanofi. The authors have no other relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.